We’re continuing to mark 50 years of Fidelity offering the Traditional IRA. Here, we break down the details on another form of IRA: the Backdoor Roth. As always, share your questions below. Fidelity Brokerage Services LLC, Member NYSE, SIPC, 900 Salem Street, Smithfield, RI 02917 1194784.5.0 ...

Oslo, 26 June 2025: Scatec ASA ("Scatec" or the "Company") will initiate a buyback of up to 68,533 of its own shares for a total maximum amount of NOK 9,600,000. The buyback programme may be carried out in the period from this announcement and until 30 June 2025. The purpose of the programme is to acquire shares that can be sold to employees as part of the Company's Employee Share Purchase Programme as announced in the stock exchange announcement published 16 June 2025 at 08.30 (CEST) in compliance with the ...

Key Takeaways MRC saw a 3% revenue rise in gas utilities, fueled by housing growth and lower energy price exposure. Increased MRO activity and data center demand are expected to support MRC's revenue growth in 2025. MRC returned $388M to shareholders in 2024 and aims to buy back $125M more under a new program through 2028.MRC Global Inc. (MRC) is benefiting from solid momentum across the gas utility sector, driven by new home construction in some U.S. states and lower exposure to energy price volatility. ...

2025 has featured no shortage of news items, from new all-time highs in the major stock market indexes in February to tariffs and trade tensions, a swift and brutal drawdown across many top stocks, a rapid recovery, and now Middle East uncertainty.Volatility is a good reminder of the importance of holding quality companies in your portfolio that you are confident in holding even when faced with the unexpected. Procter & Gamble (PG -0.85%) is one of the largest and most well-run consumer staples companies. T ...

Core Points - Wolters Kluwer has repurchased 174,141 ordinary shares for €24.7 million at an average price of €141.86 from June 19 to June 25, 2025 [2][3] - The share buyback program, announced on February 26, 2025, aims to repurchase shares up to €1 billion during 2025 [3] - Cumulatively, 3,253,150 shares have been repurchased in 2025, totaling €502.2 million at an average price of €154.38 [3] - The company has engaged third parties to execute €350 million of buybacks from May 8, 2025, to July 28, 2025 [3] - Repurchased shares will be held as treasury shares and used for capital reduction through share cancellation [4] Company Overview - Wolters Kluwer reported annual revenues of €5.9 billion in 2024 and operates in over 40 countries, employing approximately 21,900 people [6] - The company is a global leader in professional information solutions, software, and services across various sectors including healthcare, tax, accounting, and legal [5] - Wolters Kluwer shares are listed on Euronext Amsterdam and included in major indices such as AEX and Euro Stoxx 50 [7]

I think the coolest thing about InfoFi is we're getting a ton of teams pushing to market what they think is a good algorithm for determining influence, authenticity, and value.And where it gets fun is that we as users (and companies as clients) get to see how they all stack up against each other.What I'm really looking forward to is when we get enough "quality" algorithms out here, there will be some sort of influence aggregator - like a dex aggregator but for your algorithmic ranking across all of the 'maj ...

Core Viewpoint - The technology sector, particularly in the semiconductor and chipmaking industries, has become highly institutionalized, requiring investors to adapt their analysis methods to understand institutional behaviors and identify investment opportunities [1][2]. Group 1: ASML Stock Analysis - ASML's current stock price is $815.46, with a 52-week range of $578.51 to $1,110.09, and a P/E ratio of 34.29, indicating a potential upside with a price target of $913.80 [2][11]. - ASML management has been actively buying back shares, with a notable increase in purchases in June 2025, totaling 92,654 shares valued at approximately $61.4 million, reflecting confidence in the company's future valuation [4][5][6]. - Institutional investors, such as Voya Investment Management, have also shown confidence by acquiring a new stake of $14 million in ASML stock, aligning with insider buying trends [7]. Group 2: Comparative Valuation - ASML is currently trading at 68% of its 52-week high, while peers like NVIDIA and Taiwan Semiconductor are at new highs, suggesting a potential for ASML's price to catch up [9][10]. - ASML's forward P/E ratio is 23.0x, which is higher than Taiwan Semiconductor's 21.1x, indicating that ASML may be undervalued despite its lower stock price [13]. - The price-to-sales (P/S) ratio for ASML is 16.0x, significantly above Taiwan Semiconductor's 7.2x, suggesting that ASML is expected to experience higher growth and quality in sales [14].

Joining us is Brian Reynolds, the chief market strategist at Reynolds Strategy. Brian, great to see you. It's been a while, and I I don't want to fully put words in your mouth, unless I'm saying this correctly, but you're pretty bullish on the market, broadly speaking.So, you just think that the earning season itself is going to disappoint and underwhelm the explain um all of the data points that you're watching. Bullish on financial engineering, which drives stock prices higher, but the fundamentals are ch ...

Core Insights - Aclarion, Inc. has initiated the first patient enrollment in the CLARITY trial, which aims to evaluate the clinical and economic value of its Nociscan platform in spine surgery for chronic low back pain [1][6] Company Overview - Aclarion is a healthcare technology company that utilizes Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to enhance clinical treatments [5] - The company is focusing on the chronic low back pain market with Nociscan, the first evidence-supported SaaS platform designed to help physicians differentiate between painful and nonpainful discs in the lumbar spine [5] Trial Details - The CLARITY trial is a prospective, randomized multi-center study that will enroll 300 patients scheduled for surgical treatment of 1- or 2-level discogenic low back pain across multiple high-volume sites in the US [2] - The trial will randomize patients in a 1:1 ratio between surgeons who are blinded and unblinded to the Nociscan results, with the primary endpoint being the change in back pain measured on a 100mm VAS scale at 12 months compared to baseline [2][6] - The first patient was enrolled at the Texas Back Institute, which has a strong history in advancing spine care through clinical trial research [2][6] Market Context - Chronic low back pain is a significant global healthcare issue, affecting approximately 266 million people worldwide with degenerative spine disease and low back pain [3] - Aclarion's Nociscan solution aims to objectively quantify chemical biomarkers associated with disc pain, potentially leading to improved surgical outcomes [3][6]

Group 1: Company Overview - O'Reilly Automotive is an auto parts retailer that sells vehicle supplies to both consumers and professionals in a mature and competitive industry [2] - The company has shown reasonable performance in same-store sales, with a 3.6% increase in Q1 2025, and opened 38 new stores, leading to a 4% top-line growth [4] Group 2: Financial Performance - Earnings per share rose by 2%, although net income decreased by 2%, with the increase in EPS attributed to a reduction in share count due to stock buybacks [4] - The company plans to open up to 210 new locations in 2025 and expects same-store sales to grow between 2% and 4% [5] Group 3: Market Position and Valuation - O'Reilly Automotive's stock is currently considered historically expensive, with price-to-sales and price-to-earnings ratios above their five-year averages [7] - Despite recent stock price pullbacks, the decline has been less than 10% from all-time highs, indicating that the stock remains relatively high-priced [7][8] Group 4: Investment Considerations - The company faces business difficulties due to rising costs, which may impact its growth potential, making it challenging to recommend buying the stock at current prices [8][10] - Historical data shows that O'Reilly's stock has experienced common drawdowns of 25% or more, suggesting potential for deeper pullbacks in the future [11][13]